Epigenetic silencing of tumor suppressor candidate 3 confers adverse prognosis in early colorectal cancer.
Burgermeister E, Höde P, Betge J, Gutting T, Merkel A, Wu W, Tänzer M, Mossner M, Nowak D, Magdeburg J, Rückert F, Sticht C, Breitkopf-Heinlein K, Schulte N, Härtel N, Belle S, Post S, Gaiser T, Heppner BI, Behrens HM, Röcken C, Ebert MPA.
Burgermeister E, et al. Among authors: nowak d.
Oncotarget. 2017 Sep 15;8(49):84714-84728. doi: 10.18632/oncotarget.20950. eCollection 2017 Oct 17.
Oncotarget. 2017.
PMID: 29156678
Free PMC article.